Clinical Practice Guidelines for the Management of Brain Metastases from
Non-small Cell Lung Cancer with Actionable Gene Alterations in China (2025 Edition).
10.3779/j.issn.1009-3419.2024.102.42
- Collective Name:Lung Cancer Medical Education Committee of Chinese Medical Education Association;Brain Metastasis Collaboration Group, Youth Specialists Committee of Lung Cancer of Beijing Medical Reward Foundation
- Publication Type:English Abstract
- Keywords:
Actionable gene alterations;
Brain metastasis;
Clinical practice guidelines;
Lung neoplasms;
Targeted therapy
- MeSH:
Humans;
Brain Neoplasms/drug therapy*;
Carcinoma, Non-Small-Cell Lung/pathology*;
China;
Lung Neoplasms/genetics*
- From:
Chinese Journal of Lung Cancer
2025;28(1):1-21
- CountryChina
- Language:Chinese
-
Abstract:
Brain metastasis has emerged as a significant challenge in the comprehensive management of patients with non-small cell lung cancer (NSCLC), particularly in those harboring driver gene mutations. Traditional treatments such as radiotherapy and surgery offer limited clinical benefits and are often accompanied by cognitive dysfunction and a decline in quality of life. In recent years, novel small molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and other pathways have been developed, effectively penetrating the blood-brain barrier while enhancing intracranial drug concentrations and improving patient outcomes. This advancement has transformed the treatment landscape for brain metastases in NSCLC. Consequently, the Lung Cancer Medical Education Committee of the Chinese Medical Education Association and the Brain Metastasis Collaboration Group of the Lung Cancer Youth Expert Committee of the Beijing Medical Reward Foundation have jointly initiated and formulated the Clinical Practice Guidelines for the Management of Brain Metastases from Non-small Cell Lung Cancer with Actionable Gene Alterations in China (2025 Edition). This guideline integrates the latest research findings with clinical experience, adhering to multidisciplinary treatment principles, and encompasses aspects such as diagnosis, timing of intervention, and systemic and local treatment options for driver gene positive NSCLC brain metastases. Additionally, it proposes individualized treatment strategies tailored to different driver gene types, aiming to provide clinicians with a reference to enhance the overall diagnostic and therapeutic standards for NSCLC brain metastases in China.
.
